Financials Consun Pharmaceutical Group Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
5.67 ^HKD	-0.87%		+1.61%	+18.87%

Mar. 29	Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit	MT
Mar. 28	Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024	CI

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	3,418	3,507	2,053	2,848	2,820	4,164	4,164	-
Enterprise Value (EV) ¹	2,540	2,677	2,053	2,848	820.3	3,436	1,292	825.2
P/E ratio	7.54 x	44.4 x	4.21 x	4.91 x	4.16 x	4.42 x	4.6 x	4.07 x
Yield	4.27%	4.41%	9.15%	-	7.29%	5.72%	6.67%	7.81%
Capitalization / Revenue	1.85 x	2.03 x	1.17 x	-	1.21 x	1.33 x	1.42 x	1.24 x
EV / Revenue	1.38 x	1.55 x	1.17 x	-	0.35 x	1.33 x	0.44 x	0.25 x
EV / EBITDA	3.55 x	4.76 x	3.03 x	-	1.1 x	4.13 x	1.15 x	0.65 x
EV / FCF	4,529,320 x	13,151,706 x	2,508,919 x	-	-	-	-	-
FCF Yield	0%	0%	0%	-	-	-	-	-
Price to Book	1.58 x	1.76 x	0.95 x	-	0.94 x	1.09 x	0.93 x	0.79 x
Nbr of stocks (in thousands)	855,392	845,733	799,826	794,304	788,390	793,404	793,404	-
Reference price ²	3.995	4.147	2.567	3.585	3.577	5.249	5.249	5.249
Announcement Date	3/20/19	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	1,844	1,728	1,753	-	2,340	2,590	2,940	3,364
EBITDA ¹	715.7	562	676.9	-	744.8	832	1,125	1,271
EBIT ¹	644.2	488.8	605.1	-	668.4	753.9	1,042	1,208
Operating Margin	34.93%	28.29%	34.52%	-	28.57%	29.11%	35.44%	35.91%
Earnings before Tax (EBT) ¹	616.7	133.7	583.7	-	746.4	863.7	1,023	1,203
Net income ¹	465.4	79.82	498.8	590.2	682.9	784.5	928.4	1,044
Net margin	25.24%	4.62%	28.46%	-	29.19%	30.29%	31.58%	31.04%
EPS ²	0.5300	0.0934	0.6100	0.7300	0.8600	0.9800	1.140	1.290
Free Cash Flow	560.9	203.6	818.4	-	-	-	-	-
FCF margin	30.42%	11.78%	46.69%	-	-	-	-	-
FCF Conversion (EBITDA)	78.37%	36.23%	120.89%	-	-	-	-	-
FCF Conversion (Net income)	120.52%	255.04%	164.07%	-	-	-	-	-
Dividend per Share ²	0.1706	0.1828	0.2349	-	0.2606	0.3000	0.3500	0.4100
Announcement Date	3/20/19	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	877	830	-	-	2,000	2,194	2,872	3,339
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	561	204	818	-	-	-	-	-
ROE (net income / shareholders' equity)	23.8%	3.85%	23.7%	-	23.7%	22.3%	25%	23.5%
ROA (Net income/ Total Assets)	12.5%	2.1%	13%	-	14.8%	14.4%	17%	16.3%
Assets ¹	3,735	3,803	3,829	-	4,628	5,208	5,461	6,426
Book Value Per Share ²	2.520	2.350	2.700	-	3.800	4.830	5.670	6.650
Cash Flow per Share ²	0.8600	-	-	-	-	0.9700	1.120	1.290
Capex ¹	193	180	48.7	-	-	98	140	144
Capex / Sales	10.49%	10.4%	2.78%	-	-	3.71%	4.76%	4.28%
Announcement Date	3/20/19	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.249 CNY

Average target price

7.272 CNY

Spread / Average Target

+38.54%

	1st Jan change	Capi.
CONSUN PHARMACEUTICAL GROUP LIMITED	+18.87%	575M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B